SYSTEMATIC SYMPTOM ASSESSMENT IN CANCER PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS

Lung Cancer Clinical Trial

— IRMA  

Official title:

(ImmunotheRapy SyMptom CApture) A RANDOMIZED CONTROLLED TRIAL OF SYSTEMATIC SYMPTOM ASSESSMENT IN CANCER PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04929353
• Other study ID #: IRMA
• Status: Not yet recruiting
• Phase: N/A
• Start date: June 20, 2021
• Est. completion date: June 20, 2024

Study information

• Verified date: June 2021
• Source: University Of Perugia
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Immune-related adverse events (irAEs) can be different in their onset, kinetics and presentation but unlike chemotherapy are seldom predictable. Toxicity can affect nearly any organ system and multiple presentations of rare but severe irAEs have been reported, highlighting the relevance of vigilant monitoring. Although early detection and timely management of high grade or special interest irAEs (such as cardiac and neurological) is obvious, it is unclear whether early identification of less serious events can lead to clinical benefit. Furthermore, it is of the utmost importance to develop new tools which can increase identification of side effects. The current study investigates systematic symptom assessment through an electronic patient reported outcome tool and aims to define whether this can reduce the rate of serious irAEs.

Description:

Systematic collection of symptom information during immunotherapy treatment will be compared to usual care in locally advanced or metastatic lung cancer (NSCLC or SCLC) and surgically resected or advanced melanoma. Electronic survey will be administered every other day to report 14 common symptoms selected from the NCI-PRO-CTCAE TM library developed by the NATIONAL CANCER INSTITUTE (NATIONAL INSTITUTES OF HEALTH, Bethesda, Maryland) Italian version (NCI-PRO-CTCAETM ITEMS-ITALIAN-Item Library Version 1.0).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 280
• Est. completion date: June 20, 2024
• Est. primary completion date: June 20, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18 years old at time of signing Informed Consent Form
• Histologically documented diagnosis of locally advanced or metastatic lung cancer (NSCLC or SCLC), surgically resected or advanced melanoma
• Patients eligible for immunotherapy in any line of treatment, either alone or in combination with other immunotherapy drugs or with chemotherapy
• Signed Informed Consent Form
• Life expectancy =3 months
• ECOG Performance Status of =2
• Adequate hematologic and end-organ function, defined by laboratory test result by investigator's judgment
• Viral hepatitis screening:

1. Negative hepatitis B surface antigen (HBsAg) test

2. For patients with positive total HBcAb test, hepatitis B virus (HBV) DNA test is required

3. For patients with positive HCV antibody test, hepatitis C virus (HCV) RNA test is required

Exclusion Criteria:

• Patients receiving immunotherapy at time of enrollment
• > 1 grade adverse events from previous treatments
• Any uncontrolled symptom
• Clinically unstable brain metastases (i.e., symptomatic, not treated with RT and rapidly evolving)

Related Conditions & MeSH terms

• Lung Cancer
• Melanoma

Intervention

Other:
• Systematic symptom assessment
Systematic symptom assessment Conventional symptom assessment

Locations

Country	Name	City	State
Italy	Oncologia Medica, Azienda Ospedaliera Universitaria	Perugia	PG

Sponsors (1)

Lead Sponsor	Collaborator
University Of Perugia

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	1. Decrease rate of irAEs = grade 3 according to CTCAEs (Common Terminology Criteria for Adverse Events) with systematic symptom assessment	The electronic questionnaire surveys 14 symptoms selected by the NCI-PRO-CTCAE TM ITEMS-ITALIAN (Item Library Version 1.0). The patient will rate their symptoms on a 5-point ordinal scale concerning the symptom frequency (never / rarely / sometimes / often / almost always), intensity (not at all / a little / quite / a lot / very much) and sometimes their interference with usual/daily activities (not at all / a little / quite / a lot / very much). The questionnaire must be collected from all patients (ARM A and ARM B) after randomization and before first treatment administration. Patients enrolled in ARM A must answer the questionnaire every other day. Alert will then be triggered when symptom level is not within the designated range. Following every activated alert, a physical examination and biochemical blood tests must be carried out.	36 months
Secondary	1. Duration of irAEs = grade 3	Duration of irAEs = grade 3	36 months
Secondary	2. Emergency hospital admission	Emergency hospital admission	36 months
Secondary	3. Admission to and duration of hospitalization	Admission to and duration of hospitalization	36 months